Does Schedule III Marijuana Mean Insurance Covers Cannabis Cards? No

Does Schedule III marijuana mean insurance covers cannabis cards? No. DEA scheduling and FDA approval are two separate federal tracks, and only the FDA track governs what insurance pays for. Thursday's DOJ order ran on the DEA track: FDA-approved marijuana products and state-licensed medical marijuana moved into Schedule III of the Controlled Substances Act. Insurance coverage still lives on the FDA track, and the two agencies did not meet today.

By 10 a.m. Eastern on the same Thursday, every telehealth clinic in the medical cannabis business was rewriting its homepage to suggest that something had changed for patients' wallets. Something did change. It was not the thing those clinics want you to think changed. The rescheduling is real, and it matters. It just matters to dispensaries, not to your premium.

Insurance coverage follows FDA approval, not DEA scheduling

Here is the mechanism people keep missing. A substance in Schedule III can be lawfully dispensed in the United States only when the FDA has approved a specific drug product for a specific medical indication, and only when a DEA-registered practitioner writes a prescription for it that pharmacists can fill. That is the legal structure of every prescription medicine. Today's order changed where cannabis sits in the scheduling table. It did not issue a single new FDA approval.

The Congressional Research Service has said as much in plain language. A handful of cannabis-derived and cannabis-related drugs have been FDA-approved over the years, but the plant itself has not been, and Schedule III scheduling does not change that. The cannabis law firm Vicente LLP reached the same conclusion in its own analysis of the rescheduling process: dispensary cannabis products are still legally classified as "unapproved new drugs" that licensed pharmacists cannot dispense, regardless of how they are scheduled.

This is why your state-certified cannabis doctor does not write you a prescription. The visit ends with a recommendation or certification, two words chosen carefully to avoid the federal definition of "prescribe." Insurance does not reimburse recommendations. It reimburses prescriptions with an NDC code, a diagnosis code, and a pharmacy claim. Cannabis flower, vape cartridges, and gummies have none of those things. Rescheduling did not give them any of those things.

What insurance already covers in this space

Four cannabis-derived or cannabis-related drugs have cleared the FDA process and carry actual insurance coverage today. Epidiolex, a purified CBD solution approved for two rare seizure disorders, is on Medicare Part D formularies and most commercial plans. Marinol and Syndros, both synthetic THC products sold as dronabinol, are covered for chemotherapy-induced nausea and HIV-related appetite loss. Cesamet, a synthetic cannabinoid called nabilone, is similarly covered.

These drugs share three traits that nothing on a dispensary shelf shares: FDA approval for a defined indication, a National Drug Code, and a prescribing practitioner writing an order that a pharmacy can fill. Epidiolex launched at roughly $32,500 per year list price. Insured patients pay something much closer to what other branded epilepsy drugs cost: $5 to $10 a month on Medicaid, up to around $200 a month on private insurance. That is what covered-by-insurance looks like in cannabis. It does not resemble the dispensary model. For a closer parallel on how FDA-approved drug coverage actually works in practice for a patient, our guide to GLP-1 medications in 2026 walks through the same mechanics on insurance reimbursement and out-of-pocket pricing.

The IRS follows the same federal logic when deciding what counts as a medical expense for HSA or FSA purposes. Publication 502 explicitly bars controlled substances that remain illegal federally from counting as medical expenses, even in states that have legalized them. Rescheduling to III does not make state-licensed cannabis federally legal; it just makes the federal prohibition slightly less punitive. So HSA and FSA eligibility for both cannabis products and the card fees themselves stays where it was yesterday. Unchanged.

What Schedule III marijuana actually changed today

Schedule I and II substances are subject to Internal Revenue Code Section 280E, a 1982 provision written to punish cocaine dealers that got cut-and-pasted onto every state-licensed cannabis retailer in the country. Under 280E, a dispensary cannot deduct rent, payroll, marketing, security, point-of-sale software, or most operating expenses on its federal return. It pays federal tax on gross margin instead of net profit. The result routinely pushes effective tax rates above 70%, which is why only about 27% of dispensaries are profitable today, compared to roughly 65% of small businesses across the country.

Schedule III substances are not subject to 280E. That is the real consequence of today's order for patients. Once medical cannabis operators exit 280E, their effective federal tax rate falls from the current 60 to 80 percent range to something closer to the 21 to 30 percent rate that applies to ordinary businesses, which is a wholesale change to dispensary economics. Dispensaries that have spent years passing 280E costs through to customers now have the headroom to lower sticker prices, if they choose to. Some will. Some will bank the margin. Competition in each state market will determine how much flows to patients, and on what timeline.

There is a wrinkle. The DOJ's final rule today only reschedules FDA-approved products and state-licensed medical marijuana. Recreational cannabis remains Schedule I, and 280E continues to crush adult-use dispensaries. For multi-state operators that run both medical and recreational storefronts, accountants are going to have a long summer sorting out how to allocate expenses between the two. Separately, the rule asks the Secretary of the Treasury to consider retroactive 280E relief for years the operator held a medical license, which could eventually refund years of excess federal tax. That is a Treasury decision, not a DOJ one, so do not set your watch by it. Our breakdown of how federal rulemaking actually moves from announcement to effect in 2026 covers the longer timelines that surprises like this tend to hide behind.

The June 29 marijuana hearing will not fix the insurance gap either

The DOJ also announced a broader administrative hearing beginning June 29, 2026, to consider moving marijuana more generally from Schedule I to Schedule III. Even if that broader action completes, it runs into the same FDA wall. The cannabis sold at a dispensary would still not be an FDA-approved drug. It would still not carry a prescription. A pharmacy still could not dispense it. Insurance still would not cover it.

Getting insurance to pay for cannabis the way patients actually buy it requires one path and one path only: a pharmaceutical company shepherding a cannabis formulation through the full FDA approval process for a specific condition, then getting it prescribed by DEA-registered physicians. That is a multi-year, multi-hundred-million-dollar project. Nothing about today's rescheduling shortens it.

What actually reduces the cost of a cannabis card

Cards themselves run $99 to $250 on average across states, covering a doctor consultation plus, in some states, an application or renewal fee. The consultation portion has come down sharply as online cannabis card services moved the certification market onto telehealth and stripped out the overhead of in-person visits. Several state fees have already been reduced to zero. New York eliminated its state registration fee entirely. New Jersey dropped its to $10 in 2023 and then eliminated it in March 2024. New Mexico has no state fee. New Hampshire still charges $50. Michigan charges $40 for a two-year card.

State-level discount programs fill in the rest. Michigan cuts renewal to $25 for SSI recipients. Mississippi waives the application fee entirely for disabled veterans and first responders with documentation, and drops it to $15 for Medicaid recipients. Maryland offers low-income reductions. Some dispensary chains run patient assistance programs for documented hardship. None of these programs involve an insurance company or a prescription pad. They are the answer to the question "does my cannabis card cost less now," and the answer existed before today.

If you want the rescheduling to save you money, watch dispensary pricing over the next two to four quarters, not your insurance card. If you want your insurance to start covering cannabis products, watch the FDA, not the DEA. Those two agencies still have not met. Today did not introduce them. Our full health and wellness desk tracks the drug-pricing and coverage shifts most outlets only cover on announcement day.

Frequently Asked Questions

Does Schedule III marijuana mean insurance will cover cannabis cards?

No. Insurance coverage is determined by FDA approval, not DEA scheduling. The April 2026 order moved state-licensed medical marijuana and FDA-approved cannabis products to Schedule III, but it did not create any new FDA-approved cannabis drug. A dispensary product still is not prescribed, still has no National Drug Code, and still cannot be billed through a pharmacy claim. Rescheduling is real. Insurance coverage is not coming with it.

Why does insurance not pay for medical marijuana cards?

The card visit produces a recommendation or a certification, not a prescription, because cannabis flower is not an FDA-approved drug and federal law forbids a DEA-registered physician from prescribing it. Insurance only reimburses services tied to a prescription or a covered diagnosis workflow. The certification fee falls outside that system regardless of which state issued the card.

What cannabis drugs does insurance already cover?

Four: Epidiolex, a purified CBD solution for rare seizure disorders; Marinol and Syndros, both synthetic THC products sold as dronabinol for chemotherapy nausea and HIV-related appetite loss; and Cesamet, a synthetic cannabinoid called nabilone. All four have FDA approval, a National Drug Code, and a prescribing route. All four are covered on Medicare Part D and most commercial plans. None are sold at a dispensary.

Can I use an HSA or FSA to pay for a medical marijuana card?

No. IRS Publication 502 excludes federally controlled substances from counting as a qualified medical expense, even in states that have legalized them. Rescheduling to III does not reclassify state-licensed cannabis as federally legal, so the HSA and FSA rules remain unchanged. Card fees, dispensary purchases, and telehealth certifications all stay outside pre-tax medical spending accounts.

How much does a medical marijuana card cost in 2026?

Total card cost runs $99 to $250 on average across states, combining a telehealth or in-person consultation with any state registration fee. Several states have eliminated the state fee entirely (New York, New Jersey, New Mexico). Others still charge modest amounts (New Hampshire $50, Michigan $40 for two years). State-level discount programs cut the cost further for Medicaid recipients, veterans, first responders, and SSI recipients in many states.

Will dispensary prices drop because of Schedule III rescheduling?

The economic case for lower prices is real. Medical cannabis operators escape IRS Section 280E under Schedule III, which cuts their effective federal tax rate from 60 to 80 percent down to 21 to 30 percent. Whether that savings flows to patients depends on competition in each state market. Expect sticker-price movement over two to four quarters in competitive markets and margin expansion (not price cuts) in concentrated ones.